Soliris reduces kidney risks from pregnancy-associated aHUS: Study
Soliris (eculizumab) largely reduces the risk of long-term kidney problems in women who develop atypical hemolytic uremic syndrome (aHUS) during or after pregnancy, a meta-analysis study has found. “This analysis highlights the severe kidney and pregnancy outcomes associated with [pregnancy-associated aHUS],” researchers wrote, noting Soliris treatment is beneficial…